BACKGROUND: Subjective cognitive decline (SCD) in otherwise normal aging may be identified via symptom inventories in a research setting ('questionnaire-discovered complaints') or via patients seeking evaluation/services in a clinical setting ('presenting complainers'). Most studies of SCD and amyloid-β (Aβ) imaging to date have used the former approach, with inconsistent results. OBJECTIVE: To test whether 'presenting SCD' participants in an academic memory clinic setting show increased brain Aβ deposition on imaging. METHODS: Fourteen patients (mean age 68.1, SD 4.0 years) diagnosed with subjective cognitive complaints with normal neuropsychological testing were recruited into a Pittsburgh compound B (PiB)-PET study. Detailed self-report inventories and additional cognitive tests were administered. Results were compared to a reference cohort of cognitively normal volunteers (NC) from an independent neuroimaging study (mean age 73.6, SD 5.8 years). RESULTS: 57% (8/14) of SCD participants were PiB-positive by a sensitive, regionally-based definition, compared to 31% (26/84) of the NC cohort. SCD participants had significantly higher PiB retention (SUVR) than NC in three of six regions of interest: frontal cortex (p = 0.02), lateral temporal cortex (p = 0.02), and parietal cortex (p = 0.04). SCD participants showed measurable deviations on questionnaires reflecting high negative affect (i.e., depressive symptoms and neuroticism). Findings were suggestive that deficits on verbal associative binding may be specific to Aβ-positive versus Aβ-negative SCD. CONCLUSION: Older participants with SCD presenting to a memory clinic in this pilot study sample have higher brain Aβ deposition compared to normal aging study volunteers unselected on complaints. Further study of presenting SCD are warranted to determine the prognostic significance of Aβ deposition in this context.
BACKGROUND: Subjective cognitive decline (SCD) in otherwise normal aging may be identified via symptom inventories in a research setting ('questionnaire-discovered complaints') or via patients seeking evaluation/services in a clinical setting ('presenting complainers'). Most studies of SCD and amyloid-β (Aβ) imaging to date have used the former approach, with inconsistent results. OBJECTIVE: To test whether 'presenting SCD'participants in an academic memory clinic setting show increased brain Aβ deposition on imaging. METHODS: Fourteen patients (mean age 68.1, SD 4.0 years) diagnosed with subjective cognitive complaints with normal neuropsychological testing were recruited into a Pittsburgh compound B (PiB)-PET study. Detailed self-report inventories and additional cognitive tests were administered. Results were compared to a reference cohort of cognitively normal volunteers (NC) from an independent neuroimaging study (mean age 73.6, SD 5.8 years). RESULTS: 57% (8/14) of SCDparticipants were PiB-positive by a sensitive, regionally-based definition, compared to 31% (26/84) of the NC cohort. SCDparticipants had significantly higher PiB retention (SUVR) than NC in three of six regions of interest: frontal cortex (p = 0.02), lateral temporal cortex (p = 0.02), and parietal cortex (p = 0.04). SCDparticipants showed measurable deviations on questionnaires reflecting high negative affect (i.e., depressive symptoms and neuroticism). Findings were suggestive that deficits on verbal associative binding may be specific to Aβ-positive versus Aβ-negative SCD. CONCLUSION: Older participants with SCD presenting to a memory clinic in this pilot study sample have higher brain Aβ deposition compared to normal aging study volunteers unselected on complaints. Further study of presenting SCD are warranted to determine the prognostic significance of Aβ deposition in this context.
Authors: M Gagnon; J F Dartigues; J M Mazaux; L Dequae; L Letenneur; J M Giroire; P Barberger-Gateau Journal: Neuroepidemiology Date: 1994 Impact factor: 3.282
Authors: A J Saykin; H A Wishart; L A Rabin; R B Santulli; L A Flashman; J D West; T L McHugh; A C Mamourian Journal: Neurology Date: 2006-09-12 Impact factor: 9.910
Authors: J C Morris; A Heyman; R C Mohs; J P Hughes; G van Belle; G Fillenbaum; E D Mellits; C Clark Journal: Neurology Date: 1989-09 Impact factor: 9.910
Authors: Robert D Nebes; Beth E Snitz; Ann D Cohen; Howard J Aizenstein; Judith A Saxton; Edythe M Halligan; Chester A Mathis; Julie C Price; M Ilyas Kamboh; Lisa A Weissfeld; William E Klunk Journal: Neuropsychologia Date: 2013-08-01 Impact factor: 3.139
Authors: Dorene M Rentz; Terri J Huh; Robert R Faust; Andrew E Budson; Leonard F M Scinto; Reisa A Sperling; Kirk R Daffner Journal: Neuropsychology Date: 2004-01 Impact factor: 3.295
Authors: Dorene M Rentz; Joseph J Locascio; John A Becker; Erin K Moran; Elisha Eng; Randy L Buckner; Reisa A Sperling; Keith A Johnson Journal: Ann Neurol Date: 2010-03 Impact factor: 10.422
Authors: Brian J Lopresti; Elizabeth M Campbell; Zheming Yu; Stewart J Anderson; Ann D Cohen; Davneet S Minhas; Beth E Snitz; Sarah K Royse; Carl R Becker; Howard J Aizenstein; Chester A Mathis; Oscar L Lopez; William E Klunk; Dana L Tudorascu Journal: Neurobiol Aging Date: 2020-05-31 Impact factor: 4.673
Authors: David A Loewenstein; Rosie E Curiel; Maria T Greig; Russell M Bauer; Marian Rosado; Dawn Bowers; Meredith Wicklund; Elizabeth Crocco; Michael Pontecorvo; Abhinay D Joshi; Rosemarie Rodriguez; Warren W Barker; Jacqueline Hidalgo; Ranjan Duara Journal: Am J Geriatr Psychiatry Date: 2016-04-04 Impact factor: 4.105
Authors: Colette M Smart; Justin E Karr; Corson N Areshenkoff; Laura A Rabin; Carol Hudon; Nicola Gates; Jordan I Ali; Eider M Arenaza-Urquijo; Rachel F Buckley; Gael Chetelat; Harald Hampel; Frank Jessen; Natalie L Marchant; Sietske A M Sikkes; Andrea Tales; Wiesje M van der Flier; Linda Wesselman Journal: Neuropsychol Rev Date: 2017-03-07 Impact factor: 7.444
Authors: Ian M McDonough; Graham J McDougall; Michael LaRocca; Safiya G Dalmida; Kristopher L Arheart Journal: Aging Ment Health Date: 2019-04-07 Impact factor: 3.658
Authors: Jason D Flatt; Julene K Johnson; Stephen E Karpiak; Liz Seidel; Britta Larson; Mark Brennan-Ing Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Sarah M Goldberg; Oscar L Lopez; Ann D Cohen; William E Klunk; Howard A Aizenstein; Akiko Mizuno; Beth E Snitz Journal: Int Psychogeriatr Date: 2020-03-19 Impact factor: 3.878